{"nctId":"NCT01512745","briefTitle":"Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer","startDateStruct":{"date":"2011-01"},"conditions":["Advanced or Metastatic Gastric Cancer"],"count":267,"armGroups":[{"label":"apatinib","type":"EXPERIMENTAL","interventionNames":["Drug: apatinib"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"apatinib","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥ 18 and ≤ 70 years of age\n* Histological confirmed advanced or metastatic adenocarcinoma of the stomach\n* Have failed for at least 2 lines of chemotherapy\n* Life expectancy of at least 12 weeks.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 1 week before randomization.\n* At least one measurable lesion beyond stomach (larger than 10 mm in diameter by spiral CT scan)\n* Duration from the last therapy is more than 6 weeks for nitroso or mitomycin\n* More than 4 weeks for operation or radiotherapy\n* More than 4 weeks for cytotoxic agents or growth inhibitors\n* Adequate hepatic, renal, heart, and hematologic functions (HB ≥ 90g/L,platelets \\> 80 ×10 E+9/L, neutrophil \\> 1.5 × 10 E+9/L, serum creatinine ≤ 1× upper limit of normal(ULN), bilirubin \\< 1.25× ULN, and serum transaminase ≤ 2.5× ULN).\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg).\n* Any factors that influence the usage of oral administration; Evidence of Central Nerves System(CNS) metastasis\n* Intercurrence with one of the following: coronary artery disease, arrhythmia ,heart failure and proteinuria ≥ (+)\n* International Normalize Ratio (INR) \\> 1.5 and activated partial thromboplastin time（APPT） \\> 1.5 × ULN\n* Abuse of alcohol or drugs\n* Certain possibility of gastric or intestine hemorrhage\n* Less than 4 weeks from the last clinical trial\n* Prior VEGFR inhibitor treatment\n* Disability of serious uncontrolled intercurrence infection Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary function damaged seriously etc.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival(PFS)","description":"Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival(OS)","description":"Overall Survival of the Participants","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate(DCR)","description":"Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.05","spread":null},{"groupId":"OG001","value":"8.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate(ORR)","description":"Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.30","spread":null},{"groupId":"OG001","value":"90.11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":176},"commonTop":["proteinuria","leukopenia","neutropenia","elevated transaminase","hypertension"]}}}